{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T20:22:24Z","timestamp":1779222144174,"version":"3.51.4"},"reference-count":129,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"HUST Academic Frontier Youth Team","award":["2018QYTD14"],"award-info":[{"award-number":["2018QYTD14"]}]},{"name":"HUST Academic Frontier Youth Team","award":["202117"],"award-info":[{"award-number":["202117"]}]},{"name":"HUST Academic Frontier Youth Team","award":["81973995"],"award-info":[{"award-number":["81973995"]}]},{"name":"HUST Academic Frontier Youth Team","award":["82170131"],"award-info":[{"award-number":["82170131"]}]},{"name":"The Young Top-notch Talent Cultivation Program of Hubei Province","award":["2018QYTD14"],"award-info":[{"award-number":["2018QYTD14"]}]},{"name":"The Young Top-notch Talent Cultivation Program of Hubei Province","award":["202117"],"award-info":[{"award-number":["202117"]}]},{"name":"The Young Top-notch Talent Cultivation Program of Hubei Province","award":["81973995"],"award-info":[{"award-number":["81973995"]}]},{"name":"The Young Top-notch Talent Cultivation Program of Hubei Province","award":["82170131"],"award-info":[{"award-number":["82170131"]}]},{"name":"National Natural Science Foundation of China","award":["2018QYTD14"],"award-info":[{"award-number":["2018QYTD14"]}]},{"name":"National Natural Science Foundation of China","award":["202117"],"award-info":[{"award-number":["202117"]}]},{"name":"National Natural Science Foundation of China","award":["81973995"],"award-info":[{"award-number":["81973995"]}]},{"name":"National Natural Science Foundation of China","award":["82170131"],"award-info":[{"award-number":["82170131"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biology"],"abstract":"<jats:p>Protein therapeutics have been widely used to treat hematological disorders. With the advent of de novo protein design, protein therapeutics are not limited to ameliorating natural proteins but also produce novel protein sequences, folds, and functions with shapes and functions customized to bind to the therapeutic targets. De novo protein techniques have been widely used biomedically to design novel diagnostic and therapeutic drugs, novel vaccines, and novel biological materials. In addition, de novo protein design has provided new options for treating hematological disorders. Scientists have designed protein switches called Colocalization-dependent Latching Orthogonal Cage\u2013Key pRoteins (Co-LOCKR) that perform computations on the surface of cells. De novo designed molecules exhibit a better capacity than the currently available tyrosine kinase inhibitors in chronic myeloid leukemia therapy. De novo designed protein neoleukin-2\/15 enhances chimeric antigen receptor T-cell activity. This new technique has great biomedical potential, especially in exploring new treatment methods for hematological disorders. This review discusses the development of de novo protein design and its biological applications, with emphasis on the treatment of hematological disorders.<\/jats:p>","DOI":"10.3390\/biology12020166","type":"journal-article","created":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T06:52:41Z","timestamp":1674197561000},"page":"166","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["What Can De Novo Protein Design Bring to the Treatment of Hematological Disorders?"],"prefix":"10.3390","volume":"12","author":[{"given":"Hui","family":"Lu","sequence":"first","affiliation":[{"name":"Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhipeng","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang V.","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1126\/science.301.5636.1040","article-title":"Bioinformatics. Gene counters struggle to get the right answer","volume":"301","author":"Pennisi","year":"2003","journal-title":"Science"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/35087627","article-title":"International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome","volume":"412","author":"Lander","year":"2001","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1146\/annurev-med-051010-162644","article-title":"Human genome sequencing in health and disease","volume":"63","author":"Lupski","year":"2012","journal-title":"Annu. Rev. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrd2399","article-title":"Protein therapeutics: A summary and pharmacological classification","volume":"7","author":"Leader","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1056\/NEJM196609012750904","article-title":"Treatment of hemophilia with glycine-precipitated factor 8","volume":"275","author":"Abildgaard","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1182\/blood.V98.13.3600","article-title":"Human recombinant factor IX: Safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates","volume":"98","author":"Roth","year":"2001","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa040232","article-title":"A comparison of albumin and saline for fluid resuscitation in the intensive care unit","volume":"350","author":"Finfer","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1001\/jama.288.22.2827","article-title":"Efficacy of recombinant human erythropoietin in critically ill patients: A randomized controlled trial","volume":"288","author":"Corwin","year":"2002","journal-title":"JAMA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1001\/jama.283.9.1151","article-title":"Use of tissue-type plasminogen activator for acute ischemic stroke: The Cleveland area experience","volume":"283","author":"Katzan","year":"2000","journal-title":"JAMA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1056\/NEJM199211053271902","article-title":"Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin\u2019s lymphoma","volume":"327","author":"Smalley","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.264.65.1","article-title":"Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin\u2019s lymphoma B-cell lines: Role in sensitization to chemotherapeutic drug-induced apoptosis","volume":"65","author":"Jazirehi","year":"2005","journal-title":"Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S0140-6736(97)09278-7","article-title":"Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group","volume":"350","author":"Nashan","year":"1997","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2165\/00003495-200565080-00008","article-title":"Recombinant factor VIIa (Eptacog Alfa): A review of its use in congenital or acquired haemophilia and other congenital bleeding disorders","volume":"65","author":"Siddiqui","year":"2005","journal-title":"Drugs"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/ajh.26379","article-title":"Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: An update","volume":"97","author":"Lakshman","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11864-021-00925-1","article-title":"Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment","volume":"23","author":"Bock","year":"2022","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-021-01097-z","article-title":"Antibody-drug conjugates for the treatment of lymphoma: Clinical advances and latest progress","volume":"14","author":"Chu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood.2020007748","article-title":"Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells","volume":"137","author":"Daher","year":"2021","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"832645","DOI":"10.3389\/fimmu.2022.832645","article-title":"Armored BCMA CAR T Cells Eliminate Multiple Myeloma and Are Resistant to the Suppressive Effects of TGF-\u03b2","volume":"13","author":"Alabanza","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_19","unstructured":"(2018, October 03). The Nobel Prize in Chemistry 2018. Available online: https:\/\/www.nobelprize.org\/prizes\/chemistry\/2018\/summary\/."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/prot.10016","article-title":"Why are proteins marginally stable?","volume":"46","author":"Taverna","year":"2002","journal-title":"Proteins"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"100558","DOI":"10.1016\/j.jbc.2021.100558","article-title":"Recent advances in de novo protein design: Principles, methods, and applications","volume":"296","author":"Pan","year":"2021","journal-title":"J. Biol. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/nature19946","article-title":"The coming of age of de novo protein design","volume":"537","author":"Huang","year":"2016","journal-title":"Nature"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41586-022-04654-9","article-title":"Design of protein-binding proteins from the target structure alone","volume":"605","author":"Cao","year":"2022","journal-title":"Nature"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1110\/ps.051454805","article-title":"Do all backbone polar groups in proteins form hydrogen bonds?","volume":"14","author":"Fleming","year":"2005","journal-title":"Protein Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1017\/S0033583519000131","article-title":"De novo protein design, a retrospective","volume":"53","author":"Korendovych","year":"2020","journal-title":"Q. Rev. Biophys."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"167160","DOI":"10.1016\/j.jmb.2021.167160","article-title":"A Brief History of De Novo Protein Design: Minimal, Rational, and Computational","volume":"433","author":"Woolfson","year":"2021","journal-title":"J. Mol. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1021\/ar970004h","article-title":"De novo design of helical bundles as models for understanding protein folding and function","volume":"33","author":"Hill","year":"2000","journal-title":"Acc. Chem. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/nsb1297-1039","article-title":"A designed four helix bundle protein with native-like structure","volume":"4","author":"Schafmeister","year":"1997","journal-title":"Nat. Struct. Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1126\/science.282.5393.1462","article-title":"High-resolution protein design with backbone freedom","volume":"282","author":"Harbury","year":"1998","journal-title":"Science"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/nsb723","article-title":"Engineered metal binding sites map the heterogeneous folding landscape of a coiled coil","volume":"8","author":"Krantz","year":"2001","journal-title":"Nat. Struct. Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1146\/annurev.biochem.77.062906.171838","article-title":"Macromolecular modeling with rosetta","volume":"77","author":"Das","year":"2008","journal-title":"Annu. Rev. Biochem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1021\/ct500864r","article-title":"Combined covalent-electrostatic model of hydrogen bonding improves structure prediction with Rosetta","volume":"11","author":"Tyka","year":"2015","journal-title":"J. Chem. Theory Comput."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/s41586-021-04383-5","article-title":"A backbone-centred energy function of neural networks for protein design","volume":"602","author":"Huang","year":"2022","journal-title":"Nature"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature11600","article-title":"Principles for designing ideal protein structures","volume":"491","author":"Koga","year":"2012","journal-title":"Nature"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nature12966","article-title":"Proof of principle for epitope-focused vaccine design","volume":"507","author":"Correia","year":"2014","journal-title":"Nature"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1126\/science.aad8036","article-title":"Design of structurally distinct proteins using strategies inspired by evolution","volume":"352","author":"Jacobs","year":"2016","journal-title":"Science"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1021\/acs.accounts.8b00674","article-title":"De Novo Design of Four-Helix Bundle Metalloproteins: One Scaffold, Diverse Reactivities","volume":"52","author":"Lombardi","year":"2019","journal-title":"Acc. Chem. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41467-017-00541-4","article-title":"Construction and in vivo assembly of a catalytically proficient and hyperthermostable de novo enzyme","volume":"8","author":"Watkins","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1126\/science.1261172","article-title":"De novo design of a transmembrane Zn2+-transporting four-helix bundle","volume":"346","author":"Joh","year":"2014","journal-title":"Science"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"20160214","DOI":"10.1098\/rstb.2016.0214","article-title":"Design of self-assembling transmembrane helical bundles to elucidate principles required for membrane protein folding and ion transport","volume":"372","author":"Joh","year":"2017","journal-title":"Philos. Trans. R. Soc. B"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/pro.3588","article-title":"What has de novo protein design taught us about protein folding and biophysics?","volume":"28","author":"Baker","year":"2019","journal-title":"Protein Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.sbi.2015.05.009","article-title":"De novo protein design: How do we expand into the universe of possible protein structures?","volume":"33","author":"Woolfson","year":"2015","journal-title":"Curr. Opin. Struct. Biol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.tibtech.2013.10.008","article-title":"Protein folding and de novo protein design for biotechnological applications","volume":"2","author":"Khoury","year":"2014","journal-title":"Trends Biotechnol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/s41580-019-0163-x","article-title":"Advances in protein structure prediction and design","volume":"20","author":"Kuhlman","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cbpa.2019.06.011","article-title":"Towards functional de novo designed proteins","volume":"52","author":"Dawson","year":"2019","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"D\u2019Amone, L., Matzeu, G., Quijano-Rubio, A., Callahan, G.P., Napier, B., Baker, D., and Omenetto, F.G. (2022). Reshaping de Novo Protein Switches into Bioresponsive Materials for Biomarker, Toxin, and Viral Detection. Adv. Mater., e2208556.","DOI":"10.1002\/adma.202208556"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e2695","DOI":"10.1002\/jmr.2695","article-title":"Integration of molecular dynamics simulation and hotspot residues grafting for de novo scFv design against Salmonella Typhi TolC protein","volume":"31","author":"Leong","year":"2018","journal-title":"J. Mol. Recognit."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Hao, J., Serohijos, A.W., Newton, G., Tassone, G., Wang, Z., Sgroi, D.C., Dokholyan, N.V., and Basilion, J.P. (2008). Identification and rational redesign of peptide ligands to CRIP1, a novel biomarker for cancers. PLoS Comput. Biol., 4.","DOI":"10.1371\/journal.pcbi.1000138"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1021\/acs.accounts.0c00550","article-title":"De Novo Design of Flavonoid-Based Mimetics of Cationic Antimicrobial Peptides: Discovery, Development, and Applications","volume":"54","author":"Lin","year":"2021","journal-title":"Acc. Chem. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1021\/jacs.8b11939","article-title":"Simulation-Guided Rational de Novo Design of a Small Pore-Forming Antimicrobial Peptide","volume":"141","author":"Chen","year":"2019","journal-title":"J. Am. Chem. Soc."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.actbio.2017.04.032","article-title":"Disruption of drug-resistant biofilms using de novo designed short \u03b1-helical antimicrobial peptides with idealized facial amphiphilicity","volume":"57","author":"Khara","year":"2017","journal-title":"Acta Biomater."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1016\/j.bmcl.2015.07.094","article-title":"Structure-based de novo design and synthesis of aminothiazole-based p38 MAP kinase inhibitors","volume":"25","author":"Park","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1016\/j.bpj.2010.09.050","article-title":"Discovery of entry inhibitors for HIV-1 via a new de novo protein design framework","volume":"99","author":"Bellows","year":"2010","journal-title":"Biophys. J."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.str.2010.06.010","article-title":"Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope","volume":"18","author":"Correia","year":"2010","journal-title":"Structure"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1202617","article-title":"Computational design of proteins targeting the conserved stem region of influenza hemagglutinin","volume":"332","author":"Fleishman","year":"2011","journal-title":"Science"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"111628","DOI":"10.1016\/j.ejmech.2019.111628","article-title":"De novo design approaches targeting an envelope protein pocket to identify small molecules against dengue virus","volume":"182","author":"Leal","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"11263","DOI":"10.18632\/aging.103416","article-title":"De novo design of protein peptides to block association of the SARS-CoV-2 spike protein with human ACE2","volume":"12","author":"Huang","year":"2020","journal-title":"Aging"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"105728","DOI":"10.1016\/j.compbiomed.2022.105728","article-title":"De Novo design of potential inhibitors against SARS-CoV-2 Mpro","volume":"147","author":"Li","year":"2022","journal-title":"Comput. Biol. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1126\/science.abd9909","article-title":"De novo design of picomolar SARS-CoV-2 miniprotein inhibitors","volume":"370","author":"Cao","year":"2020","journal-title":"Science"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1002\/jcc.25052","article-title":"Customizable de novo design strategies for DOCK: Application to HIVgp41 and other therapeutic targets","volume":"38","author":"Allen","year":"2017","journal-title":"J. Comput. Chem."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Linsky, T.W., Vergara, R., Codina, N., Nelson, J.W., Walker, M.J., Su, W., Hsiang, T.Y., Esser-Nobis, K., Yu, K., and Hou, Y.J. De novo design of ACE2 protein decoys to neutralize SARS-CoV-2. bioRxiv, 2020.","DOI":"10.1101\/2020.08.03.231340"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Smadbeck, J., Peterson, M.B., Zee, B.M., Garapaty, S., Mago, A., Lee, C., Giannis, A., Trojer, P., Garcia, B.A., and Floudas, C.A. (2014). De novo peptide design and experimental validation of histone methyltransferase inhibitors. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0090095"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00894-020-04493-3","article-title":"Design of novel ROCK inhibitors using fragment-based de novo drug design approach","volume":"26","author":"Arya","year":"2020","journal-title":"J. Mol. Model."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s10822-019-00213-z","article-title":"Structure based design of selective SHP2 inhibitors by De novo design, synthesis and biological evaluation","volume":"33","author":"Liu","year":"2019","journal-title":"J. Comput. Aided Mol. Des."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2174\/1386207317666141029223505","article-title":"Design novel inhibitors for treating cancer by targeting Cdc25B catalytic domain with de novo design","volume":"17","author":"Wu","year":"2014","journal-title":"Comb. Chem. High Throughput Screen."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.bmcl.2011.11.124","article-title":"Structure-based de novo design and biochemical evaluation of novel BRAF kinase inhibitors","volume":"22","author":"Park","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Istivan, T.S., Pirogova, E., Gan, E., Almansour, N.M., Coloe, P.J., and Cosic, I. (2011). Biological effects of a de novo designed myxoma virus peptide analogue: Evaluation of cytotoxicity on tumor cells. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0024809"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1021\/cn500165s","article-title":"De novo design of self-assembled hexapeptides as \u03b2-amyloid (A\u03b2) peptide inhibitors","volume":"5","author":"Wang","year":"2014","journal-title":"ACS Chem. Neurosci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature10154","article-title":"Structure-based design of non-natural amino-acid inhibitors of amyloid fibril formation","volume":"475","author":"Sievers","year":"2011","journal-title":"Nature"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Rajadas, J., Liu, C.W., Novick, P., Kelley, N.W., Inayathullah, M., Lemieux, M.C., and Pande, V.S. (2011). Rationally designed turn promoting mutation in the amyloid-\u03b2 peptide sequence stabilizes oligomers in solution. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0021776"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.bbrc.2020.03.075","article-title":"Identification of protein tyrosine phosphatase 1B (PTP1B) inhibitors through De Novo Evolution, synthesis, biological evaluation and molecular dynamics simulation","volume":"526","author":"Wu","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.cell.2020.10.043","article-title":"Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2","volume":"183","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/s41586-021-03530-2","article-title":"Adjuvanting a subunit COVID-19 vaccine to induce protective immunity","volume":"594","author":"Arunachalam","year":"2021","journal-title":"Nature"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.cell.2019.01.046","article-title":"Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus","volume":"176","author":"Marcandalli","year":"2019","journal-title":"Cell"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"eaay5051","DOI":"10.1126\/science.aay5051","article-title":"De novo protein design enables the precise induction of RSV-neutralizing antibodies","volume":"368","author":"Sesterhenn","year":"2020","journal-title":"Science"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1038\/s41467-019-12080-1","article-title":"Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle","volume":"10","author":"Brouwer","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Boyoglu-Barnum, S., Ellis, D., Gillespie, R.A., Hutchinson, G.B., Park, Y.-J., Moin, S.M., Acton, O., Ravichandran, R., Murphy, M., and Pettie, D. Elicitation of broadly protective immunity to influenza by multivalent hemagglutinin nanoparticle vaccines. bioRxiv, 2020.","DOI":"10.1101\/2020.05.30.125179"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"8855","DOI":"10.1021\/acsnano.8b02805","article-title":"Engineering a Rugged Nanoscaffold To Enhance Plug-and-Display Vaccination","volume":"12","author":"Bruun","year":"2018","journal-title":"ACS Nano"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"24141","DOI":"10.1074\/jbc.M313210200","article-title":"De novo design of peptide immunogens that mimic the coiled coil region of human T-cell leukemia virus type-1 glycoprotein 21 transmembrane subunit for induction of native protein reactive neutralizing antibodies","volume":"279","author":"Sundaram","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1002\/cbic.202000407","article-title":"Synthetic Antibody Mimics Based on Cancer-Targeting Immunostimulatory Peptides","volume":"22","author":"Montel","year":"2021","journal-title":"ChemBioChem"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.1021\/nn4055732","article-title":"In vivo architectonic stability of fully de novo designed protein-only nanoparticles","volume":"8","author":"Unzueta","year":"2014","journal-title":"ACS Nano"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12951-017-0295-0","article-title":"The use of a P. falciparum specific coiled-coil domain to construct a self-assembling protein nanoparticle vaccine to prevent malaria","volume":"15","author":"Karch","year":"2017","journal-title":"J. Nanobiotechnol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1021\/acs.biomac.9b01291","article-title":"Cancer Nanomedicines Based on Synthetic Polypeptides","volume":"20","author":"Sun","year":"2019","journal-title":"Biomacromolecules"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.addr.2016.03.002","article-title":"Bioengineered protein-based nanocage for drug delivery","volume":"106","author":"Lee","year":"2016","journal-title":"Adv Drug Deliv Rev."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1073\/pnas.041614998","article-title":"Nanohedra: Using symmetry to design self assembling protein cages, layers, crystals, and filaments","volume":"98","author":"Padilla","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/nchem.2107","article-title":"Structure of a designed protein cage that self-assembles into a highly porous cube","volume":"6","author":"Lai","year":"2014","journal-title":"Nat. Chem."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/s41586-021-03258-z","article-title":"De novo design of modular and tunable protein biosensors","volume":"591","author":"Yeh","year":"2021","journal-title":"Nature"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1126\/science.abm1183","article-title":"Computational design of mechanically coupled axle-rotor protein assemblies","volume":"376","author":"Courbet","year":"2022","journal-title":"Science"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer","year":"2020","journal-title":"Nature"},{"key":"ref_90","first-page":"423","article-title":"Nanostructured bacterial materials for innovative medicines","volume":"9","author":"Villaverde","year":"2010","journal-title":"Trends Microbiol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1039\/C1CS15188F","article-title":"Toxicity of Nanomaterials","volume":"41","author":"Sharifi","year":"2012","journal-title":"Chem. Soc. Rev."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1039\/C5CS00157A","article-title":"Natural supramolecular protein assemblies","volume":"45","author":"Pieters","year":"2016","journal-title":"Chem. Soc. Rev."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1039\/C5BM00052A","article-title":"Protein nanoparticles for therapeutic protein delivery","volume":"3","author":"Champion","year":"2015","journal-title":"Biomater. Sci."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1152\/physrev.1978.58.2.317","article-title":"Ferritin: Structure, biosynthesis, and role in iron metabolism","volume":"58","author":"Munro","year":"1978","journal-title":"Physiol. Rev."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"13282","DOI":"10.1021\/ja046735b","article-title":"Engineered protein cages for nanomaterial synthesis","volume":"126","author":"Kramer","year":"2004","journal-title":"J. Am. Chem. Soc."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1107\/S2053230X17004101","article-title":"Crystal structure of a small heat-shock protein from Xylella fastidiosa reveals a distinct high-order structure","volume":"73","author":"Fonseca","year":"2017","journal-title":"Acta Crystallogr. Sect. F Struct. Biol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1021\/nn800638x","article-title":"Targeting vault nanoparticles to specific cell surface receptors","volume":"3","author":"Kickhoefer","year":"2009","journal-title":"ACS Nano"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.tibtech.2014.11.010","article-title":"Synthetic protein switches: Design principles and applications","volume":"33","author":"Stein","year":"2015","journal-title":"Trends Biotechnol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41586-019-1432-8","article-title":"De novo design of bioactive protein switches","volume":"572","author":"Langan","year":"2019","journal-title":"Nature"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1146\/annurev-biochem-060614-034124","article-title":"ATP synthase","volume":"84","author":"Junge","year":"2015","journal-title":"Annu. Rev. Biochem."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/jb\/mvr049","article-title":"Rotation and structure of FoF1-ATP synthase","volume":"149","author":"Okuno","year":"2011","journal-title":"J. Biochem."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1038\/s41564-020-0788-8","article-title":"Structures of the stator complex that drives rotation of the bacterial flagellum","volume":"5","author":"Deme","year":"2020","journal-title":"Nat. Microbiol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2017-06-786129","article-title":"Cellular kinetics of CTL019 in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia","volume":"130","author":"Mueller","year":"2017","journal-title":"Blood"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/14712598.2018.1384810","article-title":"Treating hematological malignancies with cell therapy: Where are we now?","volume":"18","author":"Landoni","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.apsb.2018.03.001","article-title":"The application of CAR-T cell therapy in hematological malignancies: Advantages and challenges","volume":"8","author":"Zhao","year":"2018","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMe2118899","article-title":"CAR T-Cell Therapy for Large B-Cell Lymphoma\u2014Who, When, and How?","volume":"386","author":"Roschewski","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_107","unstructured":"FDA (2021, April 21). Anna Kwilas, PhD, Chair of the Review Committee, OTAT\/DCGT. Summary Basis for Regulatory Action\u2014Abecma, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/abecma-idecabtagene-vicleucel."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"16011","DOI":"10.1038\/mto.2016.11","article-title":"Toxicity and management in CAR T-cell therapy","volume":"3","author":"Bonifant","year":"2016","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","article-title":"Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses","volume":"173","author":"Cho","year":"2018","journal-title":"Cell"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1021\/ci3001666","article-title":"Molecular determinants of Bim(BH3) peptide binding to pro-survival proteins","volume":"52","author":"Pinto","year":"2012","journal-title":"J. Chem. Inf. Model"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1126\/science.aba6527","article-title":"Designed protein logic to target cells with precise combinations of surface antigens","volume":"369","author":"Lajoie","year":"2020","journal-title":"Science"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nrd773","article-title":"Protein kinases--the major drug targets of the twenty-first century?","volume":"1","author":"Cohen","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41392-021-00826-7","article-title":"An overview of kinase downregulators and recent advances in discovery approaches","volume":"6","author":"Wang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.2174\/1381612822666160607220532","article-title":"De Novo Design of New Inhibitor of Mutated Tyrosine-Kinase for the Myeloid Leukemia Treatment","volume":"22","author":"Pereira","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.jaci.2010.11.050","article-title":"Interleukins, from 1 to 37, and interferon-\u03b3: Receptors, functions, and roles in diseases","volume":"127","author":"Akdis","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.0105-2896.2004.00199.x","article-title":"Cytokines in cancer immunity and immunotherapy","volume":"202","author":"Smyth","year":"2004","journal-title":"Immunol. Rev."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"15373","DOI":"10.1038\/ncomms15373","article-title":"Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells","volume":"8","author":"Loetsch","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nature10975","article-title":"Exploiting a natural conformational switch to engineer an interleukin-2 \u2018superkine\u2019","volume":"484","author":"Levin","year":"2012","journal-title":"Nature"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev-immunol-032713-120211","article-title":"Insights into cytokine-receptor interactions from cytokine engineering","volume":"33","author":"Spangler","year":"2015","journal-title":"Annu. Rev. Immunol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: The first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J. Immunol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1200\/JCO.1991.9.4.694","article-title":"Interleukin-2 toxicity","volume":"9","author":"Siegel","year":"1991","journal-title":"J. Clin. Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"11906","DOI":"10.1073\/pnas.1002569107","article-title":"Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells","volume":"107","author":"Krieg","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41586-018-0830-7","article-title":"De novo design of potent and selective mimics of IL-2 and IL-15","volume":"565","author":"Silva","year":"2019","journal-title":"Nature"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41586-019-1923-7","article-title":"Improved protein structure prediction using potentials from deep learning","volume":"577","author":"Senior","year":"2020","journal-title":"Nature"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nrd.2018.77","article-title":"Cryo-EM in drug discovery: Achievements, limitations and prospects","volume":"17","author":"Renaud","year":"2018","journal-title":"Nat. Rev. Drug. Discov."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1073\/pnas.1614519114","article-title":"Imaging proteins at the single-molecule level","volume":"114","author":"Longchamp","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.tips.2009.11.001","article-title":"Immunological mechanism underlying the immune response to recombinant human protein therapeutics","volume":"31","author":"Sauerborn","year":"2010","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1023\/B:PHAM.0000029275.41323.a6","article-title":"Structure-immunogenicity relationships of therapeutic proteins","volume":"21","author":"Hermeling","year":"2004","journal-title":"Pharm. Res."}],"container-title":["Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-7737\/12\/2\/166\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:11:54Z","timestamp":1760119914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-7737\/12\/2\/166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,20]]},"references-count":129,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["biology12020166"],"URL":"https:\/\/doi.org\/10.3390\/biology12020166","relation":{},"ISSN":["2079-7737"],"issn-type":[{"value":"2079-7737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,20]]}}}